PDS Biotechnology Corp (PDSB) - Total Liabilities
Based on the latest financial reports, PDS Biotechnology Corp (PDSB) has total liabilities worth $20.77 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
PDS Biotechnology Corp - Total Liabilities Trend (2012–2025)
This chart illustrates how PDS Biotechnology Corp's total liabilities have evolved over time, based on quarterly financial data. See working capital to net assets of PDS Biotechnology Corp to evaluate short-term liquidity relative to the company's equity base.
PDS Biotechnology Corp Competitors by Total Liabilities
The table below lists competitors of PDS Biotechnology Corp ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
FIT INVEST JSC
VN:FIT
|
Vietnam | ₫2.67 Trillion |
|
Binh Duong Trade and Development JSC
VN:TDC
|
Vietnam | ₫2.83 Trillion |
|
Sreeleathers Limited
NSE:SREEL
|
India | Rs307.33 Million |
|
CORESTEM Inc
KQ:166480
|
Korea | ₩72.65 Billion |
|
Clipper Realty Inc
NYSE:CLPR
|
USA | $1.32 Billion |
|
San Neng Group Holdings Co Ltd
TW:6671
|
Taiwan | NT$466.85 Million |
|
Orient Bell Limited
NSE:ORIENTBELL
|
India | Rs1.98 Billion |
Liability Composition Analysis (2012–2025)
This chart breaks down PDS Biotechnology Corp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see PDS Biotechnology Corp stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.26 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 5.34 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.84 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how PDS Biotechnology Corp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for PDS Biotechnology Corp (2012–2025)
The table below shows the annual total liabilities of PDS Biotechnology Corp from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $21.24 Million | -19.40% |
| 2024-12-31 | $26.35 Million | -20.76% |
| 2023-12-31 | $33.26 Million | +0.77% |
| 2022-12-31 | $33.01 Million | +727.74% |
| 2021-12-31 | $3.99 Million | +6.03% |
| 2020-12-31 | $3.76 Million | +34.62% |
| 2019-12-31 | $2.79 Million | -56.23% |
| 2018-12-31 | $6.38 Million | -78.90% |
| 2017-12-31 | $30.25 Million | +39.80% |
| 2016-12-31 | $21.64 Million | +86.29% |
| 2015-12-31 | $11.62 Million | -74.12% |
| 2014-12-31 | $44.88 Million | +86.35% |
| 2013-12-31 | $24.08 Million | +578.78% |
| 2012-12-31 | $3.55 Million | -- |
About PDS Biotechnology Corp
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers. It also develops various product candidates, which are… Read more